Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Finasteride Metabolism and Pharmacogenetics: New Approaches to Personalized Prevention of Prostate Cancer

Hulin-Curtis, Sarah L, Petit, Dominique, Figg, W Douglas, Hsing, Ann W, Reichardt, Juergen KV·2010·Future Oncology
DOI 10.2217/fon.10.149
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon.10.149

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 123

  1. 10.3322/canjclin.47.5.273 · DOI
  2. 10.1159/000474163 · DOI
  3. 10.3109/07853899309147863 · DOI
  4. 10.1073/pnas.87.10.3640 · DOI · Paper page
  5. 10.1158/0008-5472.CAN-06-4040 · DOI
  6. 10.1002/pros.10108 · DOI
  7. 10.1111/j.1749-6632.2009.04115.x · DOI
  8. Nickel JC : Comparison of clinical trials with finasteride and dutasteride.Rev. Urol.6(Suppl. 9), S31–S39 (2004).
  9. 10.1002/pros.10340 · DOI
  10. 10.1016/S0083-6729(08)60951-6 · DOI
  11. 10.1056/NEJMoa030660 · DOI
  12. 10.1016/j.urology.2004.04.084 · DOI
  13. Shahani R , FleshnerNE, ZlottaAR: Pharmacotherapy for prostate cancer: the role of hormonal treatment.Discov. Med.7, 118–124 (2007).
  14. 10.1056/NEJMe1001045 · DOI
  15. 10.1001/jama.1957.72980250010016 · DOI · Paper page
  16. 10.1080/03602530801952864 · DOI
  17. 10.1098/rstb.2005.1686 · DOI
  18. 10.1073/pnas.0407346102 · DOI · Paper page
  19. 10.1038/nrg1229 · DOI · Paper page
  20. 10.4103/0253-7613.43158 · DOI
  21. 10.1038/ncponc1303 · DOI
  22. 10.2174/138920008786049302 · DOI
  23. 10.1097/00008571-200007000-00004 · DOI
  24. 10.1038/sj.onc.1207922 · DOI
  25. 10.1677/jme.1.01725 · DOI
  26. 10.1097/MED.0b013e3282febcf6 · DOI
  27. 10.1016/S0960-9822(01)00348-7 · DOI
  28. 10.1038/ng1001-233 · DOI · Paper page
  29. 10.1038/35075590 · DOI
  30. 10.1002/gepi.20269 · DOI
  31. 10.1016/j.ymgme.2004.07.014 · DOI
  32. 10.1186/1476-069X-8-54 · DOI
  33. 10.1016/S1470-2045(09)70160-3 · DOI
  34. 10.1016/j.toxlet.2005.10.015 · DOI
  35. 10.1016/S0168-9525(01)02410-6 · DOI · Paper page
  36. 10.1093/ije/dym055 · DOI
  37. 10.1016/S0022-5347(17)71453-X · DOI
  38. Marks LS : 5α-reductase: history and clinical importance.Rev. Urol.6, S11–S21 (2004).
  39. 10.1056/NEJM199210223271701 · DOI
  40. 10.1200/JCO.2008.16.9599 · DOI
  41. 10.1016/j.ucl.2009.11.003 · DOI
  42. 10.1097/MOU.0b013e3283381966 · DOI
  43. 10.1200/JCO.2009.23.5572 · DOI
  44. 10.1093/jnci/95.14.1030 · DOI
  45. 10.1016/j.urology.2009.05.099 · DOI
  46. 10.1021/ja953069t · DOI
  47. 10.1021/ar00153a005 · DOI
  48. 10.1002/cmdc.200900252 · DOI
  49. 10.1021/bi00072a028 · DOI
  50. 10.1074/jbc.C109.016931 · DOI
  51. 10.3109/10408449209145319 · DOI
  52. 10.1016/S0140-6736(02)11203-7 · DOI · Paper page
  53. 10.1517/17425250903379546 · DOI
  54. Huskey SW , DeanDC, MillerRR, RasmussonGH, ChiuSH: Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.Drug Metab. Dispos.23, 1126–1135 (1995). · DOI
  55. 10.1016/0003-9861(88)90655-8 · DOI · Paper page
  56. 10.1067/mcp.2000.104391 · DOI
  57. Smith RL WilliamsRT: Implication of the conjugation of drugs and other exogenous compounds. In: Glucuronic Acid: Free and Combined: Chemistry Biochemistry Pharmacology and Medicine. Dutton GJ (Ed.). Academic Press NY USA 58–69 (1966). · DOI
  58. 10.1124/dmd.32.3.281 · DOI · Paper page
  59. 10.1038/sj.onc.1209375 · DOI
  60. 10.1016/j.beem.2008.01.001 · DOI
  61. 10.1016/S0009-2797(00)00198-8 · DOI · Paper page
  62. 10.3109/03602530903210682 · DOI
  63. 10.1074/jbc.M609417200 · DOI
  64. 10.1124/dmd.109.027870 · DOI
  65. 10.1124/jpet.301.1.382 · DOI
  66. 10.1146/annurev.pharmtox.40.1.581 · DOI · Paper page
  67. 10.1016/j.ejps.2008.11.009 · DOI
  68. Carlin JR , HoglundP, ErikssonLO, ChristofaloP, GregoireSL, TaylorAM: Disposition and pharmacokinetics of 14C finasteride after oral administration in humans.Drug Metab. Dispos.20, 148–155 (1992). · DOI
  69. 10.1208/pt070104 · DOI
  70. 10.1016/j.ejps.2006.04.015 · DOI
  71. 10.1007/s11095-006-9607-z · DOI
  72. Ishii Y , MukoyamaH, OhtawaM: In vivo biotransformation of finasteride in rat hepatic microsomes.Drug Metab. Dispos.22, 79–84 (1994). · DOI
  73. 10.1002/bdd.2510140406 · DOI
  74. 10.1097/00007691-200302000-00001 · DOI
  75. 10.1016/S0140-6736(98)11282-5 · DOI · Paper page
  76. 10.1002/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-B · DOI
  77. 10.1016/j.eururo.2007.04.008 · DOI
  78. 10.1016/S0039-128X(99)00010-0 · DOI
  79. 10.1016/j.ygcen.2009.12.010 · DOI
  80. 10.1016/S0169-409X(02)00066-2 · DOI · Paper page
  81. 10.1007/BF03190396 · DOI
  82. 10.1097/00008571-200007000-00001 · DOI
  83. 10.1172/JCI116064 · DOI
  84. 10.1046/j.1365-2125.1999.00073.x · DOI · Paper page
  85. Dai D , TangJ, RoseRet al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.J. Pharmacol. Exp. Ther.299, 825–831 (2001). · DOI
  86. 10.1093/jnci/90.16.1225 · DOI
  87. Paris PL , KupelianPA, HallJM, WilliamsTL, LevinH, KleinEA: Association between a CYP3A4 genetic variant and clinical presentation in African–American prostate cancer patients.Cancer Epidemiol. Biomarkers Prev.8, 901–905 (1999).
  88. 10.1159/000066695 · DOI
  89. 10.1016/j.urolonc.2005.09.005 · DOI
  90. 10.1002/humu.9432 · DOI
  91. 10.1038/sj.ejhg.5201101 · DOI
  92. 10.1038/86882 · DOI
  93. Plummer SJ , ContiDV, ParisPL, CurranAP, CaseyG, WitteJS: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.Cancer Epidemiol. Biomarkers Prev.12, 928–932 (2003).
  94. 10.1097/FTD.0b013e31811f390a · DOI
  95. 10.1007/BF03256456 · DOI
  96. 10.1038/sj.tpj.6500347 · DOI
  97. 10.1016/j.canlet.2003.12.011 · DOI
  98. 10.1080/10408360802374624 · DOI
  99. 10.1124/dmd.32.3.281 · DOI · Paper page
  100. 10.1097/00008571-200106000-00011 · DOI · Paper page
  101. 10.1002/hep.20131 · DOI
  102. 10.1007/s10038-003-0119-y · DOI
  103. 10.1016/j.eururo.2009.01.037 · DOI
  104. 10.1016/j.juro.2006.04.011 · DOI
  105. 10.1001/jama.2008.864 · DOI · Paper page
  106. 10.5489/cuaj.1129 · DOI
  107. 10.1016/S0304-3835(02)00524-4 · DOI · Paper page
  108. 10.1002/pros.21122 · DOI
  109. 10.1001/jama.1990.03450230043027 · DOI · Paper page
  110. Jasinska M , OwczarekJ, Orszulak-MichalakD: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.Pharmacol. Rep.59, 483–499 (2007).
  111. 10.1002/pds.1507 · DOI
  112. 10.1038/ncpuro1146 · DOI
  113. 10.1093/aje/kwm070 · DOI · Paper page
  114. 10.1007/s10552-009-9434-8 · DOI
  115. 10.1002/ijc.25165 · DOI
  116. 10.1056/NEJMoa0908127 · DOI · Paper page
  117. 10.1016/j.eururo.2009.09.035 · DOI · Paper page
  118. 10.1038/ng.450 · DOI
  119. 10.1002/pros.21061 · DOI
  120. 10.1158/1055-9965.EPI-09-0091 · DOI
  121. 10.1158/1055-9965.EPI-08-0317 · DOI
  122. 10.1016/S0090-4295(03)00045-1 · DOI
  123. National Center for Biotechnology Information single nucleotide polymorphisms database www.ncbi.nlm.nih.gov/snp

Cited by

Metadata

Authors
Hulin-Curtis, S. L., Petit, D., Figg, W. D., Hsing, A. W., & Reichardt, J. K.
Affiliations
  • University of Sydney, Bosch Institute, Camperdown, New South Wales, Australia: School of Pharmacy &amp; Molecular Sciences, James Cook University, Townsville, Queensland, Australia.
  • Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, MD, USA
  • Division of Cancer Epidemiology &amp; Genetics, National Cancer Institute, MD, USA
Venue
Future Oncology
Publisher
Informa UK Limited
Published
2010-12-13
Volume
6
Issue
12
Pages
1897-1913
ISSN
  • 1479-6694
  • 1744-8301
DOI
10.2217/fon.10.149
Cited by
19
References
3
Language
en
Funders
National Cancer Institute (PO1 CA108964)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.